MetaTech AP Reveals Its Strategic Growth Plan for 2027, Collaborates with Zheng Yang Biomedical in Medicine
On October 15, 2026, MetaTech AP Inc. (TPEx: 3224) held a pivotal investor conference to disclose its operational performance and strategic orientation for 2027. For the first three quarters of 2026, MetaTech recorded a revenue of NT$1.391 billion, reflecting a significant year-on-year increase of 21%. The company is focusing on electronics and biomedicine as its two main growth engines and aims to broaden its footprint in the global AI and regenerative medicine sectors.
The electronics division exhibited remarkable performance, reporting a 24.7% revenue growth compared to the previous year during the first nine months of 2026. MetaTech is keenly pursuing prospects in AI servers, power supply systems, semiconductors, and various associated applications, solidifying its market presence.
Since venturing into regenerative medicine in 2013, MetaTech has continually enhanced cell therapy technologies, specifically relating to induced pluripotent stem cells (iPSCs), and their associated therapeutic programs. The company has recently increased its collaboration with Zheng Yang Biomedical Technology Co., Ltd. to focus on the rising demand for alternatives to animal-derived materials, the enhancement of cell culture quality and safety, and the preparation for increasingly strict regulatory standards. Under this collaboration, MetaTech will take charge of manufacturing human platelet lysate (hPL), while Zheng Yang will lead global marketing and sales initiatives. The primary objective of this partnership is to seize emerging opportunities in global cell culture materials markets.
Both companies have also joined forces in the development of Elate Ocular®, a regenerative medicine product targeting dry eye disease. Plans are underway to advance clinical trials and secure regulatory approval in Taiwan, while also preparing for local manufacturing led by MetaTech AP. According to GlobalData's Dry Eye Syndrome Global Drug Forecast and Market Analysis to 2028, the dry eye therapeutics market is anticipated to grow at a compound annual growth rate (CAGR) of 10.6%, potentially reaching a value of US$11.1 billion (approximately NT$356.9 billion) by 2028. This highlights a significant market potential for innovative therapies in this space.
Alex Chen, chairman of MetaTech AP, expressed aspirations to evolve into an intelligent Contract Development and Manufacturing Organization (i CDMO) by leveraging AI-driven production. This move aims to establish Taiwan as a key production hub for regenerative medicine globally. Chen emphasized the vision of making MetaTech a preferred global partner for cell therapy manufacturing solutions. With Locus Cell, a consolidated subsidiary of MetaTech, both entities are determined to develop an integrated regenerative medicine strategy merging biomedical research with AI-fuelled manufacturing and international CDMO services.
The biomedical segment of MetaTech has shown progress on various digitalization fronts, including advancements in AI-powered Good Manufacturing Practice (GMP) document generation systems, which have successfully cut processing times for documentation by nearly one-third, resulting in reduced labor and operational costs.
In their pursuit of global partnerships, MetaTech has initiated a commercial licensing agreement pertaining to iPSC technology with iPS Academia Japan, linked to the Center for iPS Cell Research and Application (CiRA), while ongoing discussions with other Japanese firms aim to develop iPSC-derived cell therapies. Looking ahead to 2027, MetaTech AP plans to continue enhancing its electronics business related to AI technology while advancing clinical trials and local manufacturing activities in biomedicine. Furthermore, in collaboration with Locus Cell, the company seeks more international i CDMO opportunities, aiming to position Taiwan as an essential hub for global regenerative medicine technologies alongside scalable cell manufacturing capabilities.
MetaTech AP's proactive initiatives illustrate a commitment to driving growth, empowering innovation, and ultimately establishing Taiwan as a central player in the global regenerative medicine landscape.
Steady Growth in Electronics and Advances in Biomedical Developments
The electronics division exhibited remarkable performance, reporting a 24.7% revenue growth compared to the previous year during the first nine months of 2026. MetaTech is keenly pursuing prospects in AI servers, power supply systems, semiconductors, and various associated applications, solidifying its market presence.
Since venturing into regenerative medicine in 2013, MetaTech has continually enhanced cell therapy technologies, specifically relating to induced pluripotent stem cells (iPSCs), and their associated therapeutic programs. The company has recently increased its collaboration with Zheng Yang Biomedical Technology Co., Ltd. to focus on the rising demand for alternatives to animal-derived materials, the enhancement of cell culture quality and safety, and the preparation for increasingly strict regulatory standards. Under this collaboration, MetaTech will take charge of manufacturing human platelet lysate (hPL), while Zheng Yang will lead global marketing and sales initiatives. The primary objective of this partnership is to seize emerging opportunities in global cell culture materials markets.
Collaborative Development of Elate Ocular® for Dry Eye
Both companies have also joined forces in the development of Elate Ocular®, a regenerative medicine product targeting dry eye disease. Plans are underway to advance clinical trials and secure regulatory approval in Taiwan, while also preparing for local manufacturing led by MetaTech AP. According to GlobalData's Dry Eye Syndrome Global Drug Forecast and Market Analysis to 2028, the dry eye therapeutics market is anticipated to grow at a compound annual growth rate (CAGR) of 10.6%, potentially reaching a value of US$11.1 billion (approximately NT$356.9 billion) by 2028. This highlights a significant market potential for innovative therapies in this space.
Strengthening Manufacturing Capabilities
Alex Chen, chairman of MetaTech AP, expressed aspirations to evolve into an intelligent Contract Development and Manufacturing Organization (i CDMO) by leveraging AI-driven production. This move aims to establish Taiwan as a key production hub for regenerative medicine globally. Chen emphasized the vision of making MetaTech a preferred global partner for cell therapy manufacturing solutions. With Locus Cell, a consolidated subsidiary of MetaTech, both entities are determined to develop an integrated regenerative medicine strategy merging biomedical research with AI-fuelled manufacturing and international CDMO services.
The biomedical segment of MetaTech has shown progress on various digitalization fronts, including advancements in AI-powered Good Manufacturing Practice (GMP) document generation systems, which have successfully cut processing times for documentation by nearly one-third, resulting in reduced labor and operational costs.
International Collaborations and Future Outlook
In their pursuit of global partnerships, MetaTech has initiated a commercial licensing agreement pertaining to iPSC technology with iPS Academia Japan, linked to the Center for iPS Cell Research and Application (CiRA), while ongoing discussions with other Japanese firms aim to develop iPSC-derived cell therapies. Looking ahead to 2027, MetaTech AP plans to continue enhancing its electronics business related to AI technology while advancing clinical trials and local manufacturing activities in biomedicine. Furthermore, in collaboration with Locus Cell, the company seeks more international i CDMO opportunities, aiming to position Taiwan as an essential hub for global regenerative medicine technologies alongside scalable cell manufacturing capabilities.
MetaTech AP's proactive initiatives illustrate a commitment to driving growth, empowering innovation, and ultimately establishing Taiwan as a central player in the global regenerative medicine landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.